Literature DB >> 18674817

CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia.

Wei Xu1, Jian-Yong Li, Yu-Jie Wu, Hui Yu, Qiu-Dan Shen, Tian Tian, Li Li, Hong-Xia Qiu.   

Abstract

B-cell chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the Western countries, however, infrequent in the Eastern. It shows a remarkable heterogeneity, with some patients having an almost normal lifespan, others surviving only several years after diagnosis despite intensive therapy. To explore the prognostic significance of CD38 expression in Chinese patients with CLL, multi-parameter flow cytometry was used to detect the expression of CD38 on CD5(+)CD19(+) cells of 147 patients. CD38 expression and its association with some other prognostic factors such as Binet stage, lymphocyte count in peripheral blood, serum lactate dehydrogenase (LDH), beta2-microglobulin (beta2-MG), ZAP-70 expression and cytogenetic abnormalities were analyzed. The Kaplan-Meier method was used to construct survival curves, and results were compared using the log-rank test. Univariate and multivariate Cox regression analyses were used to assess associations between survival time and potential risk factors. Out of the 147 CLL patients, positive expression of CD38 was found in 45 (30.6%) cases. CD38-positivity identified a subgroup of CLL patients with aggressive disease of Binet stage at the time of the test (P=0.036). Furthermore, the presence of higher serum LDH and beta2-MG levels at diagnosis was strongly correlated with CD38-positive (P=0.016 and 0.025, respectively). Prognostically unfavorable cytogenetic abnormalities, including 17p13 and 11q22 deletions, were significantly more frequent in CD38-positive patients than in CD38-negative ones (P=0.047 and 0.001, respectively). There was no significant difference between CD38-positive and CD38-negative groups in molecular cytogenetic aberrations of del(6q23), del(13q14), 14q32 translocation, or trisomy 12. In addition, in CD38-positive patients, the percentage of leukemic cells expressing ZAP-70 protein was not significantly higher than in CD38-negative ones (P=0.120). CD38 expression was associated with poor outcome. Patients with positive expression of CD38 had significantly shorter overall survival (mean, 81 months) than patients without CD38 expression (mean, 179 months) (P=0.015). Univariate analysis showed that serum levels of LDH and beta2-MG, del(17p13) and CD38 expression were the significant factors in determining overall survival (OS). Del(17p13) and CD38 expression were the variables strongly associated with OS by multivariate Cox regression analysis. It was showed that the patients with high level of CD38 expression had poorer outcome; CD38 was a good predictor of OS in Chinese patients with CLL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18674817     DOI: 10.1016/j.leukres.2008.06.026

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.

Authors:  Cheng Fang; Yun Zhuang; Li Wang; Lei Fan; Yu-Jie Wu; Run Zhang; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Wei Xu; Jian-Yong Li
Journal:  Cancer Sci       Date:  2013-06-07       Impact factor: 6.716

2.  Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.

Authors:  Min Xu; Lei Fan; Kou-Rong Miao; Peng Liu; Wei Xu; Jian-Yong Li
Journal:  Med Oncol       Date:  2011-09-01       Impact factor: 3.064

3.  Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.

Authors:  Yin-Hua Wang; Zhi-Jian Zou; Ling Liu; Li-Na Zhang; Cheng Fang; Dan-Xia Zhu; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

4.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

5.  Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.

Authors:  Wen-Ting Wang; Hua-Yuan Zhu; Yu-Jie Wu; Yi Xia; Jia-Zhu Wu; Wei Wu; Jin-Hua Liang; Li Wang; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-03       Impact factor: 4.553

6.  Association between polymorphism of GLI1 gene SNP rs2228226 and chronic lymphocytic leukemia in Chinese population.

Authors:  Yuan-Yuan Li; Tian Tian; Run Zhang; Li Wang; Ji Xu; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2014-10-29       Impact factor: 3.064

7.  Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

Authors:  Wei Xu; Xin Cao; Kou-Rong Miao; Chun Qiao; Yu-Jie Wu; Qiong Liu; Lei Fan; Jian-Yong Li
Journal:  Int J Hematol       Date:  2009-07-24       Impact factor: 2.490

8.  Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia.

Authors:  Marilisa Marinelli; Caterina Ilari; Yi Xia; Ilaria Del Giudice; Luciana Cafforio; Irene Della Starza; Sara Raponi; Paola Mariglia; Silvia Bonina; Zhen Yu; Wenjuan Yang; Lugui Qiu; Thomas Chan; Alfonso Piciocchi; Yok-Lam Kwong; Eric Tse; Jianyong Li; Anna Guarini; Wei Xu; Robin Foà
Journal:  Oncotarget       Date:  2016-04-12

9.  Prognostic markers in Chronic Lymphocytic Leukaemia - A flow cytometric analysis.

Authors:  Hala Haq; Nasir Uddin; Saleem Ahmed Khan; Sunia Ghaffar
Journal:  Pak J Med Sci       Date:  2020 Mar-Apr       Impact factor: 1.088

10.  [Abnormal expression of WWP1 in chronic lymphocytic leukemia and its clinical significance].

Authors:  C Q Yang; L Cao; R Huang; H L Liu; Y J Wu; C Qiao; W Xu; J Y Li; L Fan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.